G9a: An Emerging Epigenetic Target for Melanoma Therapy

Overview

Journal Epigenomes

Date 2021 Oct 25

PMID 34691767

Citations 5

Authors

Jessica L Flesher

David E Fisher

Affiliations

Soon will be listed here.

Abstract

Epigenetic regulation is a crucial component of DNA maintenance and cellular identity. As our understanding of the vast array of proteins that contribute to chromatin accessibility has advanced, the role of epigenetic remodelers in disease has become more apparent. G9a is a histone methyltransferase that contributes to immune cell differentiation and function, neuronal development, and has been implicated in diseases, including cancer. In melanoma, recurrent mutations and amplifications of G9a have led to its identification as a therapeutic target. The pathways that are regulated by G9a provide an insight into relevant biomarkers for patient stratification. Future work is aided by the breadth of literature on G9a function during normal differentiation and development, along with similarities to EZH2, another histone methyltransferase that forms a synthetic lethal relationship with members of the SWI/SNF complex in certain cancers. Here, we review the literature on G9a, its role in melanoma, and lessons from EZH2 inhibitor studies.

Citing Articles

EHMT2 promotes tumorigenesis in -mutant uveal melanoma ARHGAP29-mediated RhoA pathway.

Li Y, Zhu T, Yang J, Zhang Q, Xu S, Ge S Acta Pharm Sin B. 2024; 14(3):1187-1203.

PMID: 38486999 PMC: 10935147. DOI: 10.1016/j.apsb.2023.12.002.

Molecular and functional anticancer effects of GLP/G9a inhibition by UNC0646 in MeWo melanoma cells.

Filiu-Braga L, Silva-Carvalho A, Sousa M, Carvalho J, Saldanha-Araujo F Heliyon. 2024; 10(5):e27085.

PMID: 38434406 PMC: 10907798. DOI: 10.1016/j.heliyon.2024.e27085.

A Review of Advanced Cutaneous Melanoma Therapies and Their Mechanisms, from Immunotherapies to Lysine Histone Methyl Transferase Inhibitors.

de Oliveira Filho R, de Oliveira D, Nisimoto M, Marti L Cancers (Basel). 2023; 15(24).

PMID: 38136297 PMC: 10741407. DOI: 10.3390/cancers15245751.

C2H2 Zinc Finger Transcription Factors Associated with Hemoglobinopathies.

Zhang X, Xia F, Zhang X, Blumenthal R, Cheng X J Mol Biol. 2023; 436(7):168343.

PMID: 37924864 PMC: 11185177. DOI: 10.1016/j.jmb.2023.168343.

Targeting Histone Epigenetic Modifications and DNA Damage Responses in Synthetic Lethality Strategies in Cancer?.

Lazo P Cancers (Basel). 2022; 14(16).

PMID: 36011043 PMC: 9406467. DOI: 10.3390/cancers14164050.

References

Kato S, Weng Q, Insco M, Chen K, Muralidhar S, Pozniak J . Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis. Cancer Discov. 2020; 10(7):980-997. PMC: 7334057. DOI: 10.1158/2159-8290.CD-19-0532. View

Helming K, Wang X, Wilson B, Vazquez F, Haswell J, Manchester H . ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med. 2014; 20(3):251-4. PMC: 3954704. DOI: 10.1038/nm.3480. View

Bergin C, Zouggar A, Haebe J, Masibag A, Desrochers F, Reilley S . G9a controls pluripotent-like identity and tumor-initiating function in human colorectal cancer. Oncogene. 2020; 40(6):1191-1202. PMC: 7878189. DOI: 10.1038/s41388-020-01591-7. View

Golan T, Levy C . Negative Regulatory Loop between Microphthalmia-Associated Transcription Factor (MITF) and Notch Signaling. Int J Mol Sci. 2019; 20(3). PMC: 6387231. DOI: 10.3390/ijms20030576. View

Barski A, Cuddapah S, Cui K, Roh T, Schones D, Wang Z . High-resolution profiling of histone methylations in the human genome. Cell. 2007; 129(4):823-37. DOI: 10.1016/j.cell.2007.05.009. View

Peters A, OCarroll D, Scherthan H, Mechtler K, Sauer S, Schofer C . Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell. 2001; 107(3):323-37. DOI: 10.1016/s0092-8674(01)00542-6. View

Shin H, Kapoor V, Guan T, Kaech S, Welsh R, Berg L . Epigenetic modifications induced by Blimp-1 Regulate CD8⁺ T cell memory progression during acute virus infection. Immunity. 2013; 39(4):661-75. PMC: 3808842. DOI: 10.1016/j.immuni.2013.08.032. View

Damsky W, Curley D, Santhanakrishnan M, Rosenbaum L, Platt J, Gould Rothberg B . β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell. 2011; 20(6):741-54. PMC: 3241928. DOI: 10.1016/j.ccr.2011.10.030. View

Wen B, Wu H, Shinkai Y, Irizarry R, Feinberg A . Large histone H3 lysine 9 dimethylated chromatin blocks distinguish differentiated from embryonic stem cells. Nat Genet. 2009; 41(2):246-50. PMC: 2632725. DOI: 10.1038/ng.297. View

10.

Ciechomska I, Przanowski P, Jackl J, Wojtas B, Kaminska B . BIX01294, an inhibitor of histone methyltransferase, induces autophagy-dependent differentiation of glioma stem-like cells. Sci Rep. 2016; 6:38723. PMC: 5146656. DOI: 10.1038/srep38723. View

11.

Sampath S, Marazzi I, Yap K, Sampath S, Krutchinsky A, Mecklenbrauker I . Methylation of a histone mimic within the histone methyltransferase G9a regulates protein complex assembly. Mol Cell. 2007; 27(4):596-608. DOI: 10.1016/j.molcel.2007.06.026. View

12.

Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

13.

Karimi M, Goyal P, Maksakova I, Bilenky M, Leung D, Tang J . DNA methylation and SETDB1/H3K9me3 regulate predominantly distinct sets of genes, retroelements, and chimeric transcripts in mESCs. Cell Stem Cell. 2011; 8(6):676-87. PMC: 3857791. DOI: 10.1016/j.stem.2011.04.004. View

14.

Artal-Martinez de Narvajas A, Gomez T, Zhang J, Mann A, Taoda Y, Gorman J . Epigenetic regulation of autophagy by the methyltransferase G9a. Mol Cell Biol. 2013; 33(20):3983-93. PMC: 3811684. DOI: 10.1128/MCB.00813-13. View

15.

Yang Z, Qi Y, Lai N, Zhang J, Chen Z, Liu M . Notch1 signaling in melanoma cells promoted tumor-induced immunosuppression via upregulation of TGF-β1. J Exp Clin Cancer Res. 2018; 37(1):1. PMC: 5755139. DOI: 10.1186/s13046-017-0664-4. View

16.

Bao L, Chen Y, Lai H, Wu S, Wang J, Hatanpaa K . Methylation of hypoxia-inducible factor (HIF)-1α by G9a/GLP inhibits HIF-1 transcriptional activity and cell migration. Nucleic Acids Res. 2018; 46(13):6576-6591. PMC: 6061882. DOI: 10.1093/nar/gky449. View

17.

Kleer C, Cao Q, Varambally S, Shen R, Ota I, Tomlins S . EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003; 100(20):11606-11. PMC: 208805. DOI: 10.1073/pnas.1933744100. View

18.

Serre C, Busuttil V, Botto J . Intrinsic and extrinsic regulation of human skin melanogenesis and pigmentation. Int J Cosmet Sci. 2018; 40(4):328-347. DOI: 10.1111/ics.12466. View

19.

Maeda K, Hamada J, Takahashi Y, Tada M, Yamamoto Y, Sugihara T . Altered expressions of HOX genes in human cutaneous malignant melanoma. Int J Cancer. 2004; 114(3):436-41. DOI: 10.1002/ijc.20706. View

20.

Li Q, Dong C, Cui J, Wang Y, Hong X . Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme. J Exp Clin Cancer Res. 2018; 37(1):265. PMC: 6208043. DOI: 10.1186/s13046-018-0941-x. View